Upload
milton-alexander
View
215
Download
0
Embed Size (px)
DESCRIPTION
3 Title I General Provisions Title II Maximum Residue Limits Chapter I risk assessment and risk management Section 1 pharm active substances intended for use in vmps Section 2 pharm active substances not intended for use in vmps Chapter II Classification Title III Reference points for action Structure of the Regulation
Citation preview
1
FVE General AssemblyBrussels, 17 November 2007
Maximum Residue Levels
2
Proposal for a Regulation
Laying down procedures for the establishment of residue limits of pharmacologically
active substances in foodstuffs of animal origin
• Co-decision• 1rst reading in European Parliament
3
Title I General Provisions
Title II Maximum Residue LimitsChapter I risk assessment and risk management
Section 1 pharm active substances intended for use in vmps
Section 2 pharm active substances not intended for use in vmps
Chapter II Classification
Title III Reference points for action
Structure of the Regulation
4
Classification4 classes of substances (Comp. to Annexes 1, 3, 2 and 4 of Regulation 2377/90)
1. A maximum residue limitOn the base of opinion of CVMPVote by Community in Codex Alimentarius (see 6)
2. A provisional maximum residue limitIncomplete data
3. The absence of a maximum residue limitNot necessary for protection of human health
4. A prohibition on the administration of a substanceWhere any use constitutes a hazard
5
Extrapolation
The committee shall - when carrying out risk assessments and drawing up risk management conditions - consider using
MRLs established for a pharmacol. active substance– in a particular foodstuff for another foodstuff derived from the same species,
or – in one or more species for other species
6
Community contributes in Codex Alimentarius to development of international standards on MRLs.
The Community should take over without further risk assessment those Codex Alimentarius limits it has supported.
7
Extrapolation and adopting of MRLs
already accepted in the Codex Alimentarius will reduce the investments needed for the development of new products
Will contribute to solve the problem of product availability
8
In Parliament for 1rst reading
Introducing further safety factorsProcedure with scrutiny by EPIntroducing extra hurdles for marketing
authorisations